Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen

[1]  U. Mellqvist,et al.  Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.

[2]  Kihyun Kim,et al.  Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma , 2014, BioMed research international.

[3]  J. H. Lee,et al.  Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study , 2014, American journal of hematology.

[4]  D. Lüftner,et al.  Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. , 2014, European journal of cancer.

[5]  Je-Jung Lee,et al.  Decreased body mass index is associated with poor prognosis in patients with multiple myeloma , 2014, Annals of Hematology.

[6]  W. Anderson,et al.  Improved long-term survival in multiple myeloma up to the age of 80 years , 2014, Leukemia.

[7]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[8]  M. Dimopoulos,et al.  Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens , 2011, Leukemia & lymphoma.

[9]  R. Wäsch,et al.  Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score , 2011, Blood cancer journal.

[10]  E. Anaissie,et al.  Infections in patients with multiple myeloma. , 2009, Seminars in hematology.

[11]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[12]  C. Dejong,et al.  Pathophysiology of cancer cachexia: much more than host-tumour interaction? , 2007, Clinical nutrition.

[13]  P. Dickman,et al.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Esterni,et al.  Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia , 2007, Cancer.

[15]  N. Munshi,et al.  High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[18]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[19]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[20]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[21]  C. Cerveró,et al.  Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients—diagnostic and clinical implications , 1998, Clinical and experimental immunology.

[22]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[23]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[24]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[25]  M. Oken,et al.  Influence of treatment and response status on infection risk in multiple myeloma. , 1981, The American journal of medicine.

[26]  Osgood Ee The survival time of patients with plasmocytic myeloma. , 1960 .

[27]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[28]  M. Dimopoulos,et al.  Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  P. Valent,et al.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Rossi,et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.

[31]  E. E. Osgood The survival time of patients with plasmocytic myeloma. , 1960, Cancer chemotherapy reports.

[32]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.